Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 5/20 | 0.47 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065494 | 1.00 | XIAP (0.48) | XIAPCALCRLRENCMA1RAMP1 | |
| SCHEMBL29521253 | 0.94 | CALCRL (0.49) | XIAPCALCRLRENRAMP1CAPN1 | |
| SCHEMBL29630482 | 0.93 | OPRM1 (0.46) | XIAPRENCMA1SLC6A2CAPN1 | |
| SCHEMBL30335933 | 0.88 | NTSR2 (0.47) | CALCRLRENCAPN1NTSR2NTSR1 | |
| SCHEMBL30239989 | 0.87 | XIAP (0.49) | XIAPRENCAPN1NTSR2NTSR1 | |
| SCHEMBL30525434 | 0.85 | CALCRL (0.50) | XIAPCALCRLRENCMA1RAMP1 | |
| SCHEMBL31083914 | 0.85 | ACE (0.56) | REN | |
| SCHEMBL29883844 | 0.85 | OPRM1 (0.50) | XIAPRENCMA1SLC6A2CAPN1 | |
| SCHEMBL30401176 | 0.84 | SLC6A2 (0.49) | XIAPCALCRLRENCMA1SLC6A2 | |
| SCHEMBL29351166 | 0.84 | KMT2A (0.51) | XIAPSLC6A2CAPN1CTSBNTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292615-A1 | DIAGNOSIS AND TREATMENT OF DISEASE | MOLECULAR SKINCARE LIMITED (GB) | 2008-11-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292615-A1 | DIAGNOSIS AND TREATMENT OF DISEASE | SERPINB1, EPCAM, DNASE1L3 | XIAP 1921/4885CALCRL 1553/4885REN 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.